Novartis International AG /Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.
↧